Who are Autologous monocytes's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Casgevy, IL-2 pre-treated CD19 cells, Stem Cell, Concentrated Bone Marrow Aspirate Injection, 3ml-Rejuvinex, Cord Blood Cell.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/autologous-monocytes.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Autologous monocytes — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Autologous monocytes (Autologous monocytes) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Cell therapy; autologous cellular immunotherapy. Area: Immunology; Regenerative Medicine.

phase 3 Cell therapy; autologous cellular immunotherapy Immunology; Regenerative Medicine Biologic Live · refreshed every 30 min

Target snapshot

Autologous monocytes (Autologous monocytes) — Aivita Biomedical, Inc.. Autologous monocytes are a patient's own immune cells that are isolated, potentially modified or activated ex vivo, and reinfused to enhance immune function and promote tissue repair.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Autologous monocytes TARGET	Autologous monocytes	Aivita Biomedical, Inc.	phase 3	Cell therapy; autologous cellular immunotherapy
Casgevy	EXAGAMGLOGENE AUTOTEMCEL		marketed	Autologous genome-edited hematopoietic stem cell therapy	BCL11A	2023-01-01
IL-2 pre-treated CD19 cells	IL-2 pre-treated CD19 cells	jiangjingting	marketed	Adoptive cell therapy	CD19
Stem Cell	Stem Cell	Neurogen Brain and Spine Institute	marketed	Cell therapy
Concentrated Bone Marrow Aspirate Injection	Concentrated Bone Marrow Aspirate Injection	Hospital for Special Surgery, New York	marketed	Autologous stem cell therapy
3ml-Rejuvinex	3ml-Rejuvinex	Seoul National University Bundang Hospital	marketed	Autologous cell therapy
Cord Blood Cell	Cord Blood Cell	China Spinal Cord Injury Network	marketed	Cell therapy

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Cell therapy; autologous cellular immunotherapy class)

Aivita Biomedical, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Autologous monocytes — Competitive Intelligence Brief. https://druglandscape.com/ci/autologous-monocytes. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing